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ABSTRACT 
It is generally accepted that somatostatin receptor subtype 5 (SSTR5) mediates the 
inhibition of insulin release. This is due to the fact that in the human, rat and mouse, 
somatostatin (SST) inhibits insulin release via SSTR5. However, in a preliminary study from 
Dr. Hsu's laboratory with HIT-T15 ~-cells that are derived from hamster insulinoma, it was 
found that a SSTR2 agonist but not other SSTR agonists inhibited insulin release. Since 
SSTR2 is also highly expressed in tumor cells, it is possible that the results from HIT-Tl5 
cells may be due to the nature of tumor cells. Thus it is hypothesized that in hamsters SSTR2 
mediates somatostatin-induced inhibition of insulin release. Isolated hamster pancreatic islets 
were used in the present study to test this hypothesis. Both somatostatin ( 1-100 nM) and 
nonpeptide SSTR2 agonist L-779,976 (0.1-100 nM) inhibited insulin release in a dose-
dependent manner. Nonpeptide agonists for SSTRI, 3, 4, and 5 at the highest concentration 
studied (lµM) failed to inhibit insulin release. PRL-2903, a peptide SSTR2 antagonist (0.3 -
1 µM), antagonized somatostatin-induced inhibition of insulin release in a dose-dependent 
manner. It is concluded that in hamster ~-cells, somatostatin inhibits insulin release via 
SSTR2 but not SSTR5. 
CHAPTERl.GENERALINTRODUCTION 
Thesis Organization 
This thesis is written in an alternative thesis format. It contains of a general 
introduction including literature review and a list of references cited, one manuscript, a 
general conclusion, and acknowledgements. Chapter 2, "Somatostatin inhibits insulin release 
via SSTR2 in the hamster pancreatic islets," will be submitted to Regulatory Peptides. 
Literature Review 
Pancreas: 
In mammals, the pancreas is located in the abdominopelvic cavity, and contains 
exocrine and endocrine glands (Figure 1 A). The exocrine gland is composed of acinar cells, 
which accounts for 97- 99% of the pancreas (Hsu and Crump, 1989). The exocrine gland of 
the pancreas releases digestive enzymes such as lipase, protease and amylase to digest lipid, 
protein and carbohydrate respectively. 
The endocrine gland of the pancreas also is called the islets of Langerhans. The islets 
consist of four types of endocrine cells:ex cells, (3 cells, o cells and F cells, which release 
glucagon, insulin, somatostatin (SST) and pancreatic polypeptide, respectively (Figure 1 B) 
(Pelletier, 1997). The (3 cells account for 75 % of the islets (Karam, 1995). The ex cells 
account for 20 % of the islets and are located in the periphery of the islets (Karam, 1995). 
Theo cells account for 3% of the islets and are located between ex cells and (3 cells (Karam, 
1995). The F cells are the least numerous cells in the islets, comprising about 2 % of the 
islets (Karam, 1995). 
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Figurel. Structure of an islet of Langerhans in the pancreas. (A) A human pancreatic 
islet (lightly stained) is surrounded by acinar cells. (B) A schematic of a pancreatic islet. (3 
cells, which release insulin form the core of the pancreatic islet. a cells, 8 cells and F cells 
surround (3 cells and release glucagon, SST and pancreatic peptide, respectively (modified 
from Nussey and Whitehead, 2001). 
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The main effect of the pancreatic islets is to control fuel homeostasis (Ganong, 
2001 ). In starvation, glucagon released from ex cells evokes gluconeogenesis and 
glycogenolysis in the liver to maintain blood glucose concentration. When the blood glucose 
concentration is increased ( e.g. after a meal), insulin is released from (3 cells, evoking 
glycogen synthesis in the liver and glucose uptake into skeletal muscle to decrease blood 
glucose concentration. SST can inhibit both insulin and glucagon release to stop fuel 
utilitization and biosynthesis (Ganong, 2001). Pancreatic peptide slows down food 
absorption, but its exact physiological function is still unknown (Ganong, 2001). 
Insulin: 
1. Insulin synthesis: 
The gene and structure of insulin are highly conserved through evolution (Ganong, 
2001). In humans, preproinsulin is encoded on the short arm of chromosome 11, which is 
close to the gene of insulin-like growth factor 2 (IGF-2) (Ganong, 2001). There are three 
exons and two introns (Figure 2 -1) for encoding preproinsulin mRNA (Figure 2-2). 
Preproinsulin has four parts: signal peptide, A chain, B chain and connecting peptide (C 
peptide) (Nussey and Whitehead, 2001). Preproinsulin is transported to rough endoplasmic 
reticulum (RER) and the signal peptide is removed by proteolytic enzymes to form proinsulin 
(Figure 2-3). The only difference between proinsulin and insulin is C peptide, which 
connects A and B chains in proinsulin. Proinsulin is transported to the Golgi apparatus by 
microvesicles (Nussey and Whitehead, 2001). There are two endopeptidases and carboxyl 
peptidase H to rapidly cleave C peptide from proinsulin to form insulin (Figure 2-4). Insulin 
and C peptide are transported by secetory granules (Figure 2-5), and are released 
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Figure 2. Pathway oflnsulin synthesis. (1) The structure of human preproinsulin RNA. (2) 
After RNA processing, preproinsulin mRNA is formed. (3) Signal sequence is cleaved from 
preproinsulin to form pro insulin in RER. ( 4) C peptide is cleaved from pro insulin to form 
insulin in Golgi apparatus. (5) Insulin and C peptide are co-transported in vesicle and co-
secreted into bloodstream (modified from Nussey and Whitehead, 2001). 
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simultaneously. The amount of C-peptide can be used to indicate the amount of endogenous 
insulin release in patients with type 2 diabetes receiving exogenous insulin (Ganong, 2001). 
The half-life of insulin in the blood stream is approximately 5 minutes (Ganong, 2001). 
2. Insulin release: 
Insulin is released through exocytosis of secretory granules. The general procedures 
of exocytosis are docking, priming, fusion and release (Figure 3) (Barg, 2003). 
Insulin granules are transported to the plasma membrane where they dock. As 
illustrated in Fig. 4A, vesicle soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (v-SNAREs), such as vesicle-associated membrane protein 2 (V AMP-2) or also 
called synaptobrevin, are attached to insulin granule membrane. Target membrane soluble N-
ethylmaleimide-sensitive factor attachment protein receptors (t-SNAREs), such as soluble N-
ethylmaleimide-sensitive factor attachment protein 25 ( SNAP-25 ) and syntaxin 1, are 
attached to the plasma membrane (Scheller, 1996; Bittar and Howell, 1999 and Lang, 1999). 
During docking, v-SNAREs and t-SNAREs twist together to form a parallel four-helix 
bundle, which can pull the granule close to L-type voltage-dependent Ca2+ channels 
(VDCCs) in the plasma membrane (Figure 4B) (Sollner et al., 1993; Sutton et al., 1998). 
Priming occurs after docking, which includes hydrolysis of ATP by N-
ethylmaleimide (NEM) -sensitive factor (NSF), an A TPase (Klenchin and Martin, 2000). 
Priming is in the ATP-dependent manner, but the role of ATP in the priming is unclear. 
According to a recent study, PKA and PKC use ATP to phosphorylate SNAREs complex for 
exocytosis (Klenchin and Martin, 2000). 
Insulin secretion is triggered by Ca2+ that flows into cell via L-type VDCC. 
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Figure 3. A schematic of insulin release. An insulin granule is transported to the plasma 
membrane and then docked. Priming includes phosphorylation of proteins involved in 
exocytotic pathway. Ca2+ triggers insulin release (modified from Barg, 2003). 
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Figure 4. Proteins interaction in insulin exocytosis. (A) An insulin granule is near the 
plasma membrane for docking. (B) t-SNAREs interact with v-SNAREs to form a parallel 
four-helix bundle. Ca2+ interacts with synaptotagmin to cause fusion. (C) After insulin 
release, the SNARE complex is dissociated by NSF to hydrolyze ATP to phosphorylate this 
protein complex and the granule is recycled (modified from Barg, 2003). 
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Synaptotagrnin, located on the insulin granule membrane, serves as a Ca2+ sensor. Two 
isoforms have been identified, synaptotagrnin III and VII (Lang et al., 1997; Gao et al., 
2000). Synaptotagrnin has two Ca2+ -binding domains, C2A and C2B (Sutton et al., 1995). 
After binding with ca2+, insulin granules fuse with the plasma membrane to release insulin. 
After fusion, SNARE protein complex is dissociated by NSF to hydrolyze ATP to 
phosphorylate this protein complex (Figure 4 C) and the granule is recycled (Sudhof, 2000). 
3. Regulation of insulin release: 
Insulin release is induced by secretagogues including glucose, amino acids, and short 
chain fatty acids . Insulin release can be regulated by many neural endocrine substances 
through their G protein-coupled receptors. In this section, I will discuss hyperglycemia-
induced insulin release and G protein-regulated insulin release. 
(1) Hyperglycemia-induced insulin release: 
Glucose is the most potent secretagogue for insulin release (Ganong, 2001). When 
blood glucose concentration increases, glucose enters (3 cells throug GLUT-2 transporters 
(Figure 5). In (3 cells, glucose is phosphorylated by hexokinase and then metabolized in the 
mitochondria to produce ATP (Ganong, 2001). Then ATP binds sulfonylurea receptors of the 
ATP-sensitive K+ channels to close ATP-sensitive K+ channels. With the closure of these 
channels, the plasma membrane depolarizes. Eventually, L-type VDCCs are activated and 
Ca2+ flows into the cell (Ashcroft and Rosman, 1989). 
Synapsin 1 tethers insulin vesicles with the cytoskeleton. When intracellular Ca2+ 
concentration ([Ca2+]i) is increased, Ca2+ binds with calmodulin. Ca2+ /calmodulin in tum 
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Figure 5. A schematic of glucose-induced insulin release. Glucose enters the {3 cell via 
GLUT2 transporter. After glucose is metabolized in the mitochondrion, ATP is produced, 
which elevates ATP/ ADP ratio, and closes ATP-sensitive potassium channels, resulting in 
cell depolarization. Ca2+ influx is via L-type Ca2+ channels (VDCCs). Ca2+ triggers insulin 
release (modified from Barg, 2003). 
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activates calmodulin dependent kinase II (CAM kinase II), which phophorylates synapsin 1 
and changes its conformation to release insulin vesicles (Easom, 1999). Subsequently, insulin 
vesicles dock with the plasma membrane and insulin is released into the extracellular fluid 
(Sutton et al., 1995). 
There are two phases for glucose-induced insulin release (Figure 6). In the first 
phase, the insulin granules are released approximately every 3 seconds (Sharp, 2002). The 
granules in the first phase come from the readily releasable pool and the first phase is 
sustained for approximately 5 minutes (Nussey and Whitehead, 2001). The first phase is due 
to release of preformed insulin by increased [Ca2+]i. In the second phase, insulin granules are 
released approximately every 10 seconds (Sharp, 2002). The second phase usually lasts 30 
minutes (Nussey and Whitehead, 2001). The second phase is due to release of granules in the 
reserve pool, which translocate to the readily releasable pool by CAM kinase II, PKA, and 
PKC to phosphorylate proteins of exocytotic pathway (Easom, 1999). 
(2) Gs-mediated insulin release: 
The heterotrimeric GTP-binding protein (G protein) is a signal-coupling protein, 
which mediates signal transduction from the seven transmembranes receptor (serpentine 
receptor). A G protein consists of a, (3, and 'Y subunits; (3 and 'Y subunits form a dimer (Figure 
7). The a subunit has a guanyl nucleotide binding site, which belongs to the P-loop NTPase 
family. In the inactive state, GDP is bound with G protein. When the receptor is bound with 
its ligand, the ligand-bound receptor catalyzes the exchange of GTP to GDP in the G protein 
and thus G protein is in the active state. In the active state, the a subunit dissociates from the 
(3"( dimer. The Ga and (3"( dimer can transmit signals. Subsequently the a subunit hydrolyzes 
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Figure 6. Two phases of glucose-induced insulin release. The first phase sustains 
approximately 5 minutes and the second phase sustains approximately 30 minutes (modified 
from Nussey and Whitehead, 2001). 
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Figure 7. The heterotrimeric G protein cycle. G protein is a heterotrimer consisting of a, (3, 
and 'Y subunits. In the inactive state, GDP is bound with G protein. The ligand-bound receptor 
catalyzes the exchange of GTP to GDP in the G protein and thus G protein is in the active 
state. In the active state, the a subunit dissociates from the (3-y dimer. The Ga and (3-y dimer 
can transmit signals. Subsequently the Ga subunit hydrolyzes GTP to GDP and associates 
with (3-y dimer to tum off signal transduction (modified from Berg et al., 2002). 
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GTP to GDP and associates with {3-y dimer to tum off signal transduction (Berg et al., 2002). 
There are three kinds of G proteins, Gs (s for stimulatory), G9 and Gi/o (i for inhibitory, o for 
olfactory), to regulate insulin release. 
Hormones such as glucagon and glucagon like peptide-I (GLP-1) can activate Gs-
coupled receptors on (3 cells, resulting in insulin release (Figure 8) (Sharp, 1979 and 1996). 
After a Gs-coupled receptor is activated, a subunit of Gs not only opens VDCCs to increase 
[Ca2+]i but also activates adenylyl cyclase in the plasma membrane (Conn and Melmed 
1997). The activated adenylyl cyclase increases cAMP formation. Consequently, cAMP 
binds to the regulatory subunits of cAMP-dependent protein kinase (PKA) and regulatory 
subunits dissociate from catalytic subunits to complete the activation process (Berg et al., 
2002). Activated PKA can phosphorylate the sulfonylurea receptors of the ATP-sensitive K+ 
channels and then the ATP-sensitive K+ channels can be maintained in the closed state to 
depolarize the plasma membrane (Inagaki et al., 1995). PKA phosphorylates the a1 subunits 
of the L-type VDCCs to open these channels and thus increases insulin release (Leiser and 
Fleischer, 1996). PKA also phosphorylates synapsin 1. Synapsin 1 tethers insulin vesicles 
with cytoskeleton and changes its conformation to release insulin vesicles from the reserve 
pool to the readily releasable pool (Renstrom et al., 1997). 
(3) Gq-mediated insulin release: 
Some ligands activate G9-coupled receptors, such as cholinergic M3 receptor, on (3 
cells, which also can increase insulin release (Figure 8) (Prentki, 1987). After G9-coupled 
receptor is bound by its ligand, a subunit of G9 activates phospholipase C-{3 (PLC-{3), which 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) 
T mm ddu i:e 
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CCK 
GIP 
Figure 8. Gs and Gq signal transduction in insulin release. Hormones such as GLP-1 and 
cholecystokinin-pancreozymin can activate Gq and G5-couped receptors respectively on the 
pancreatic (3 cell, which also can regulate insulin release. AC, adenylyl cyclase; Ach, 
acetylcholine; CaMK, calmodulin dependent kinases; CCK, cholecystokinin-pancreozymin; 
DAG, diacylglycerol; ER, endoplasmic reticulum; GIP, gastric inhibitory peptide; GLP-1, 
glucagon-like peptide-I; IP3, inositol 1, 4, 5-trisphosphate; PKA, protein kinase A; PKC, 
protein kinase C; PLC, phospholipase C (modified from Cerasi et al., 2002). 
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and diacylglycerol (DAG). IP3 activates its receptors on the smooth endoplasmic reticulum 
(ER) to release Ca2+ from the ER and elevates [Ca2+]i (Ganong, 2001). DAG and Ca2+ can 
activate PKC. PKC, like PKA, also can phophorylate synapsin 1 to cause the conformational 
change, releasing insulin vesicles from cytoskeleton. Insulin vesicles move from the reserve 
pool to the readily releasable pool (Gillis et al, 1996; Stevens and Sullivan, 1998; Sudhof, 
2000). 
(4) Gi/0-mediated inhibition of insulin release: 
Some hormone such as SST can activate Gi10-coupled receptor on (3 cells (Figure 9) 
(Tallent et al., 1992). After Gi/0-coupled receptor is bound with its ligand, ex subunit of Gi/o 
can directly close VDCCs (Conn and Melmed 1997), open K+ channels (Conn and Melmed 
1997) and inhibit adenylyl cyclase (Conn and Melmed 1997). Consequently, the inhibition of 
adenylyl cyclase leads to a decrease in PKA activation. The sulfonylurea receptors of the 
ATP-sensitive K+ channels cannot be phosphorylated due to lack of PKA activation and then 
the A IP-sensitive K+ channels cannot be maintained in the closing state to depolarize the 
plasma membrane. The a1 subunits of the L-type VDCCs cannot be phosphorylated due to 
lack of PKA activation and then the L-type 
VDCCs cannot be maintained in the open state. Thus, Ca2+ cannot flow into the cell to trigger 
insulin release. 
(5) Somatostatin-induced inhibition of insulin release: 
(i) Somatostatin synthesis: 
PreproSST is transcripted and translated by the long arm of chromosome 3 (Patel, 
16 
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Figure 9. Gi/o protein signal transduction in insulin release. Hormones such as SST can 
activate Gu0 -coupled receptor on the pancreatic (3 cell, which also can inhibit insulin release 
(modified from Patel, 1999). 
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1999). Then preproSST is processed into two kinds of polypeptides (SST-14 and SST-28) 
(Ganong, 2001). SST-14 and its amino terminal-extended form, SST-28, contain 14 and 28 
amino acid residues, respectively. Both of them are the active forms. Phe7, Trp8, Lys9 and 
Thr10 in SST form a (3 tum, which interact with SSTR (Figure 10) (Patel, 1999). The amount 
of SST-14 and SST-28 in the neural tissues, pancreatic islets and stomach are variable due to 
different SST-producing cells and precursor processing. SST-14 is an exclusive form in 
enteric neurons and peripheral nerves in the retina. SST-14 is a dominant form in the neural 
tissues, pancreatic islets and the stomach. In brain, SST-28 accounts for 20~30 % of total 
SST (Patel et al., 1999). 
(ii) Somatostatin release: 
SST is released from neurons and 8 cells by exocytosis. In the hypothalamus, growth 
hormone-releasing hormone, corticotropin-releasing hormone and neurotensin can stimulate 
SST release from hypothalamus via Gs, Gs, and G9-coupled receptor, respectively (Patel, 
1999). Gamma aminobutyrate (GABA) can inhibit SST release from hypothalamus via 
GABAA receptor, an iontropic receptor (Cr channel) and GABA8 receptor (Gi/0 -coupled 
receptor). When GABAA receptor is bound with GABA, er channel is opened and then er 
flows into cells. Consequently, L-type VDCC is inactivated by hyperpolarization and SST 
release is inhibited. 
In the pancreas, glucagon can stimulate SST release via a Gs-coupled receptor (Patel, 
1999). The nutrient effect is tissue specific particularly in the pancreatic 8 cells. Glucose, 
lipid and amino acids can stimulate 8 cells to release SST. The plasma half-life of SST is 
short, probably no longer than 3 minutes (Patel and Wheatley, 1983). 
18 
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Figure 10. The structures of somatostatin-14 and -28 and other peptide agonists. SST-14 
and its amino terminal-extended form, SST-28, contain 14 and 28 amino acid residues, 
respectively. Both of them are in the active form. Phe7, Trp8, Lys9 and Thr10 in SS form the 
active site in SST. SMS 201-995 is an octreotide that has a high affinity for SSTR2, SSTR3, 
and SSTR5 (see Table 1 on page 26). BIM23014 is a lanreotide that has a high affinity for 
SSTR2 and SSTR5. RC-160 is a vapreotide that also has a high affinity for SSTR2 and 
SSTR5. DC32-87, an octapeptide, displays a high affinity for SSTR2 and moderate affinity 
for SSTR5. DC32-92, a linear octapeptide, displays a high affinity for SSTR5 and a moderate 
affinity for SSTR3. SSTR peptide agonists are not as selective as SSTR nonpeptide agonists 
for the SSTR subtype characterization. 
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(iii) Actions of somatostatin: 
SST is secreted by o cells of the pancreatic islets, the central and peripheral nervous 
systems, and similar o cells in the gastrointestinal mucosa (Figure 10) (Ganong, 2001 ). 
In the central and peripheral nervous system SST acts as a neurotransmitter to inhibit 
the release of other neurotransmitters and hormones such as growth hormone, thyrotropin-
releasing hormone, thyroid-stimulating hormone, corticotropin-releasing hormone, 
acetylcholine, norepinephrine and, dopamine (Gray et al., 1989; Patel, 1999). 
SST can inhibit endocrine secretion of the gastrointestinal tract and pancreas, such as 
gastrin, vasoactive intestinal peptide, gastric inhibitory peptide, insulin, glucagon and 
pancreatic polypeptide. SST also can inhibit exocrine secretion in the gut such as gastric acid, 
pepsin, and bile salt (Patel, 1999; Ganong, 2001). Motor activity such as gastric emptying, 
gallbladder contraction, and small intestinal segmentation also can be suppressed because 
SST inhibits the release of acetylcholine (Gray et al., 1989). 
(iv) Regulation of somatostatin release: 
In the islets, SST release can be regulated through a paracrine relationship (Figure 11 
A). Theo cells in pancreatic islets have dendritic processes, which can reach into the 
periphery and core of the pancreatic islets to contact a and (3 cells, respectively (Nussey and 
Whitehead, 2001). Glucagon directly stimulates o cells to induce SST release. Then SST can 
directly inhibit glucagon and insulin released from a and (3 cells, respectively (Ganong, 
2001). 
SST release also can be regulated through an endocrine relationship (Figure 11 B). In 
the islets, the arterial blood is derived from superior mesenteric, hepatic and splenic arteries 
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Figure 11. The distribution of cel1s and blood vessels in the pancreatic islet. (A) The~ 
cells are located in the core of the islet and the a cells, o cells and F cells are located in the 
periphery area of the islet. (B) This graph illustrates the distribution of the blood vessels in 
the pancreatic islet (modified from Nussey and Whitehead, 2001 ). 
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(Nussey and Whitehead, 2001 ). Capillaries are distributed to the islets and blood is drained 
into superior mesenteric and splenic veins. Glucagon is released into capillaries in the 
pancreatic islets (Nussey and Whitehead, 2001). Then glucagon is transported too cells to 
induce SST release. Consequently, SST is released and inhibits glucagon and insulin release 
from ex cells and (3 cells, respectively. 
(v) Somatostatin receptors: 
Somatostatin receptors and subtypes: 
Somatostatin receptor (SSTR) is a typical G protein-coupled receptor (GPCR), which 
has 7 ex helical transmembrane domains (Figure 12) (Tallent et al., 1992). There are 5 
somatostatin receptor subtypes (SSTR1-SSTR5) (Yamada et al., 1992). All five SSTR 
subtypes have a remarkable degree of structural conservation among species (Reisine et al., 
1995). Gene encoding SSTR2 in humans, rats and mice can be divided into SSTR2A and 
SSTR2B (Patel, 1999; Sellers et al., 2000). SSTR2A and SSTR2B differ only in the length of 
the cytoplasmic tail. All of them are Gu0 -coupled receptors. SST-14 and SST-28 have similar 
binding affinities with SSTR1- SSTR4. SST28 has a higher binding affinity with SSTR5 than 
other SSTRs (Patel et al, 1994; 1995 and 1996). The results of an immunohistochemical 
study indicate that SSTR5 is expressed predominantly in the rat (3 cells (Mitra et al., 1999) 
and the amount of SST-28 in the pancreas is much lower than SST-14. Thus SSTR5 has a 
higher binding affinity with SST-28 to mediate its physiological signals. 
SSTR expression: 
All 5 SSTR subtypes are expressed in the pancreatic islets and stomach (Patel, 1999; 
Weckbecker et al., 2003). The brain expresses SSTRl-4 (Patel, 1999; Bruns et al., 2003). 
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Figure 12. The structure of SSTR2A. Somatostatin is a typical G protein-coupled receptor, 
which has 7 transmembrane domains. Gene encoding SSTR2 in humans, rats and mice can 
be divided into SSTR2A and SSTR2B. SSTR2A (369 amino acids) and SSTR2B (356 amino 
acids) are only different in their carboxyl termini, respectively. Asn276 and Phe294 in outer 
part of 6th and 7th transmembrane domains form active site to interact with SST (modified 
from Weckbecker et al., 2003). 
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The pituitary gland expresses SSTRl-3 and SSTR5 (Patel, 1999; Weckbecker et al., 
2003).The kidney expresses SSTRI and SSTR2. The liver, lymphocytes, T cells, lung and 
lymphoid express SSTRI, SSTR2, SSTR3, SSTR4, and SSTR5, respectively (Patel, 1999; 
Weckbecker et al., 2003). Different SSTR subtypes can mediate different physiological 
processes in different tissues. For examples, SSTR2 and SSTR5 are expressed predominantly 
in the rat pancreatic ex and (3 cells, respectively, and mediate antisecretory signal to glucagon 
and insulin, respectively (Rossowski et al., 1994; Hunyady et al., 1997; Mitra et al., 1999). In 
the human lymphocytes, SSTR3 mediates apoptosis signal (Lattuada et al., 2002). In the 
CHO-Kl cells, SSTRl and SSTR4 mediate growth arrest signals (Bito et al., 1994; Florio et 
al., 1999). 
Receptor ligand binding domain: 
There is no X ray crystallography study of SSTR. The study of SSTR binding 
domain is achieved by using SST analogs (Patel, 1999). 
SMS 201-995, an octreotide, is a SST analog that has a high affinity for SSTR2, 
SSTR3, and SSTR5. Results of a SMS 201-995 study indicate that the predicted SSTR 
binding domain, composed of a number of noncontinuous amino acid residues, is in a 
binding pocket form (Kaupmann et al., 1995). Asn276 and Phe294 in outer part of 6th and 7th 
transmembrane domains are the core part to interact with Phe, Trp, Lys and Thr in SMS 201-
995 (Figure 10) (Bauer et al., 1982; Veber et al. 1984; Taylor et al., 1997). Asp 137 in the outer 
part of the 3rd transmembrane domain can fix with Lys9 in SMS 201-995 due to electrostatic 
interaction (Patel 1999). SST analog study revealed that the active site of SSTR can be used 
to develop new pharmacological agents. 
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(vi) Somatostatin-induced inhibition of insulin release: 
SSTR is a Gi10-coupled receptor (Tallent et al., 1992). The Ga subunit of the SSTR 
not only inhibits adenylyl cyclase but also activates serine/threonine protein phosphatase 
such as calcineurin (Renstrom et al., 1996; Gromada et al., 2001; Weckbecker et al., 2003). 
Calcineurin can dephophorylate the a1 subunit of the L-type VDCC and the sulfonylurea 
receptor of the ATP-sensitive K+ channel. Subsequently the L-type VDCC cannot be 
maintained in the opening state and Ca2+ cannot flow into the cell to trigger insulin release. 
The ATP-sensitive K+ channel cannot be maintained in the closing state to keep plasma 
membrane depolarization. 
(vii) SSTR peptide agonists: 
Phe7, Trp8, Lys9 and Thr10 are the critical sequence of SST to recognize SSTR. In 
SSTR peptide agonists, DTrp and Lys are essential residues to form /3 tum (Patel, 1999). Phe 
and Thr can be substituted for other amino acids, which have similar properties. For example, 
Phe can be replaced by Tyr and Thr can be replaced by Ser or Val (Patel, 1999). 
For example, SMS 201-995 is an octreotide that has a high affinity for SSTR2, 
SSTR3, and SSTR5 (Patel, 1999). BIM23014 is a lanreotide that has a high affinity for 
SSTR2 and SSTR5 (Patel, 1999). RC-160 is a vapreotide that also has a high affinity for 
SSTR2 and SSTR5 (Patel, 1999). SMS 201-995, BIM23014, and RC-160 are octapeptides 
and also have hexapeptide cores formed by Cys2 and Cys 7, which form disulfide bond 
(Figure 9) (Patel, 1999). DC32-87, an octapeptide, displays a high affinity for SSTR2 and a 
moderate affinity for SSTR5 (Figure 10) (Table 1 ). DC32-92, a linear octapeptide, displays a 
high affinity for SSTR5 and a moderate affinity for SSTR3 (Figure 10) (Table 1 ). 
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Table 1. Binding affinities of SSTR peptide agonists, non peptide agonists, peptide 
antagonists and nonpeptide antagonists for the clonal human SSTRs (modified from 
Hocart et al., 1999; Patel 1999 and Weckbecker et al., 2003). 
ICso (nM) 
Compound hSSTRl hSSTR2 hSSTR3 hSSTR4 hSSTR5 
Peptide agonists 
SMS 201-995 290 0.4-2.1 4.4-34.5 >1000 5.6-32 
BIM23014 500 0.5-1.8 43-107 66 0.6-14 
RC-160 >1000 5.4 31 45 0.7 
DC32-87 7820 0.65 244 970 6.8 
DC32-92 98 18 5.6 127 1.2 
Nonpeptide agonists 
L-797,591 1.4 1875 2240 170 3600 
L-779,976 2760 0.05 729 310 4260 
L-796,778 1255 > 10,000 24 8650 1200 
L-803 ,087 199 4720 1280 0.7 3880 
L-817,818 3.3 52 64 82 0.4 
Peptide antagonists 
PRL-2868 37±9.5 176±88 382±181 >1000 972±411 
PRL-2903 >1000 26 ± 3.1 231 ± 102 >1000 535±116 
SST3-ODN-8 >10,000 >10,000 6.7 >10,000 >10,000 
TT-232 >10,000 >10,000 >10,000 900 >10,000 
BIM23056 337 132 177 234 12.1 
Nonpeptide antagonists 
SRA-880 9.8 36300 8710 15100 1445 
BN-81674 > 10,000 >10,000 0.92 >10,000 >10,000 
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Most SSTR peptide agonists have higher affinities for at least two SSTR subtypes 
(Table 1). Consequently, they are not as selective as nonpeptide agonists for SSTR subtype 
characterization (Table 1 ). 
(viii) SSTR nonpeptide agonists: 
SSTR nonpeptide agonists are made by combinatorial chemistry (Schaeffer et al., 
1998). 
L-363,377, a cyclic hexapeptide SSTR2 agonist, was used as a probe for molecular 
modeling (Schaeffer et al., 1998). There were approximately 200,000 random compounds 
formed from L-363,377 modeling. L-264,930, SSTR2 nonpeptide agonist, was the most 
potent of these compounds. L-264,930 was treated by combinatorial chemistry and large 
populations of molecules were formed (Schaeffer et al., 1998). L-797,591 , L-779,976, L-
796,778, L-803,087 and L-817,818 selected from molecules are the most potent nonpeptide 
agonists for SSTRl, SSTR2, SSTR3, SSTR4 and SSTR5, respectively (Figure 13 and Table 
1 ). These SSTR nonpeptide agonists are small molecules that may be developed into an oral 
pharmacological agent that is able to cross the blood-brain barrier (Schaeffer et al., 1998). 
(viv) SSTR peptide antagonists: 
Most SSTR peptide antagonists are made from an octapeptide template (Weckbecker 
et al., 2003). Most octapeptide antagonists have Lys4-DTrp5, because Lys4-DTrp5 forms the 
center of a {3 tum, which is critical for receptor recognition (Hocart et al., 1999). Some 
peptide antagonists have a cyclic hexapeptide core formed by two cysteine residues that form 
disulfide bond (Hocart et al., 1999). Other peptide antagonists do not form a cyclic 
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Figure 13. Structures of SSTR non peptide agonists. (modified from Schaeffer et al., 
1998). 
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hexapeptide core and are called linear antagonists. Linear antagonists still form the critical {3 
turn conformation to recognize SSTR (Hocart et al. , 1999). 
PRL-2868 and PRL-2903 are SSTRl and SSTR2 octapeptide antagonists, 
respectively (Figure 14). Both antagonists have the critical {3 tum conformation formed by 
Lys4-DTrp5 and cyclic hexapeptide cores formed by Cys2 and Cys7, which form disulfide 
bond (Hocart et al., 1999). SST3-ODN-8, a SSTR3 octapeptide antagonist, has N-methyl-
amino-2-napthoyl amino glycine instead of tryptophan in the {3 tum conformation. SST3-
ODN-8 is a cyclic octapeptide formed by Cys 1 and Cys8, which form disulfide bond (Figure 
14) (Weckbecker et al., 2003). BIM-23056 is a linear SSTR5 octapeptide antagonist and its {3 
turn conformation is formed by Lys4-DTrp5 (Figure 14) (Weckbecker et al., 2003). TT-232 is 
a SSTR4 heptapeptide antagonist, in which the {3 tum conformation is formed by Lys3-DTrp4 . 
TT-232 has a cyclic pentopeptide core formed by Cys2 and Cys6, which form disulfide bond 
(Figure 14) (Weckbecker et al., 2003). SSTR peptide antagonists are not as selective as 
SSTR nonpeptide agonists for the SSTR subtype characterization (Table 1). 
(x) SSTR nonpeptide antagonists: 
SRA-880 is a SSTRl nonpeptide antagonist, which is derived from 
octahydrobenzoquinoline (Figure 15) (Hoyer et al., 2004). BN-81674 is a SSTR3 nonpeptide 
antagonist, which is derived from tetrahydro-{3-carboline (Figure 15) (Poitout et al., 2001). 
The selectivity of both nonpeptide antagonists is higher than that of peptide antagonists 
(Table 1). Nonpeptide antagonists for SSTR2, SSTR4, and SSTR5 are still not available. 
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Figure 14. Structures of SSTR peptide antagonists. 
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SRA-&&•O (SSTRl antagonist) BN-81674 (SSTR3 antagonist) 
Figure 15. Structures of SSTR nonpeptide antagonists. SRA-880 and MN-81674 are 
SSTRl and SSTR3 nonpeptide antagonists, respectively (see Table 1 on Page 26) (modified 
from Weckbecker et al., 2003). 
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Abstract 
Somatostatin inhibits pancreatic endocrine secretion. It is generally accepted that 
SSTR2 and SSTR5 mediate the inhibition of glucagon and insulin release, respectively. In a 
preliminary study with HIT-Tl 5 B-cells that are derived from hamster insulinoma, we found 
that a SSTR2 agonist, but not other SSTR agonists, inhibited insulin release. Thus we 
hypothesized that in hamsters, SSTR2 mediates somatostatin-induced inhibition of insulin 
release. Isolated hamster pancreatic islets were used in the present study to test this 
hypothesis. Both somatostatin and nonpeptide SSTR2 agonist L-779,976 (0.1-100 nM) 
inhibited insulin release in a dose-dependent manner. In contrast, nonpeptide agonists for 
SSTRl, 3, 4, and 5 at the highest concentration studied (1 µM) failed to inhibit insulin 
40 
release. PRL-2903 , a peptide SSTR2 antagonist (0.3 - 1 µM) , antagonized somatostatin-
induced inhibition of insulin release in a dose-dependent manner. We conclude that in 
hamster ~-cells, somatostatin inhibits insulin release via SSTR2 but not SSTR5. 
Introduction 
Somatostatin (SST), a peptide hormone, is secreted by o cells of the pancreatic islets, 
the central and peripheral nervous systems, and the gastrointestinal mucosa [ 1]. In the central 
and peripheral nervous systems, SST acts as a neurotransmitter to inhibit the release of other 
neurotransmitters and hormones such as growth hormone, thyrotropin-releasing hormone, 
thyroid-stimulating hormone, corticotropin-releasing hormone, adrenocorticotropic hormone, 
acetylcholine, norepinephrine and dopamine [2] . SST also can inhibit endocrine secretions of 
the gastrointestinal tract and pancreas, such as gastrin, vasoactive intestinal peptide, gastric 
inhibitory peptide, insulin, glucagon and pancreatic polypeptide [ 1, 2]. 
Somatostatin receptor (SSTR), a Gi/0 -coupled receptor, has 5 subtypes (SSTR1-
SSTR5) [3, 4]. All 5 SSTR subtypes have a remarkable degree of structural conservation 
among mammalian species [ 5]. The pancreatic islets and stomach express all 5 SSTR 
subtypes [2, 6] , the brain expresses SSTRI-4 [2, 7] , the pituitary gland expresses SSTRI-3 
and SSTR5 [2, 6] , the kidney expresses SSTRl and SSTR2, whereas the liver, lymphocytes, 
T cells, lung and lymphoid express SSTRl, SSTR2, SSTR3, SSTR4, and SSTR5, 
respectively [2, 6] . 
It is generally accepted that SSTR5 mediates SST-induced inhibition of insulin 
release [8] because in the rats, mice, and humans studies, SST inhibits insulin release via 
SSTR5 [9, 10, 11]. However, according to our preliminary findings in clonal {3-cells HIT-Tl 5 
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that are derived from hamster insulinoma, SST inhibits insulin release via SSTR2 
(unpublished data). Since SSTR2 is also highly expressed in tumor cells [2, 12], it is possible 
that the results from HIT-T15 cells may be due to the nature of tumor cells and not 
extrapolate to the physiological pancreas of hamster. We hypothesized that SSTR2 mediates 
the inhibition of insulin release in hamster pancreatic ,6-cells. Thus, we used hamster 
pancreatic islets to characterize the SSTR subtype that mediates inhibition of insulin release. 
In our study, we used highly selective SSTR nonpeptide agonists to functionally characterize 
the SSTR subtype in pancreatic ,6-cells [2, 13]. We also used PRL-2903, a SSTR2 peptide 
antagonist [14], to help characterize the SSTR subtype that mediates SST-induced inhibition 
of insulin release in this species. 
Materials and Method 
Test agents 
All reagents were obtained from Sigma chemical (St. Louis, MO, U.S.A.), except 
that the SSTR selective nonpeptide agonists, L-797,591 (SSTRl), L-779,976 (SSTR2), L-
796,778 (SSTR3), L-803,087 (SSTR4), and L-817,818 (SSTR5), were kindly donated by 
Merck Research Laboratories (West Point, PA, U.S.A.); the SSTR 2 antagonist (PRL-2903) 
was synthesized by D. H. Coy. 
Animals 
Male, mixed-breed hamsters (80 ~ 100 g) were used in these experiments. The 
hamsters were anesthetized with pentobarbital sodium (60 mg/kg, ip). The hamsters were 
operated in a lamina flow hood to maintain the sterility. Following a midline incision to the 
abdomen to expose the pancreas, 5 ml of sterile Krebs-Ringer bicarbonate buffer (KRB, pH 
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7.4), supplemented with 10 mM HEPES, 5.5 mM glucose, was injected using a 27-gauge 
needle to two sites of the pancreas (2.5 ml in each site) to inflate it. These two sites are 
located near the spleen and stomach, respectively. The inflated pancreas was removed and 
transferred to a 5-ml sterile dish containing KRB and was minced into fragments of 1 to 2 
mm3. The fragments were digested in 1 ml of KRB with type 5 collagenase (2.8 mg/ml, 
Sigma, St Louis, Mo) in a sterile 15-ml centrifuge tube. The tube was shaken in a 37 ° C 
water bath for 7 min. After digestion, 12 ml of KRB was added to dilute the collagenase. The 
tube was centrifuged at 1850 x g for 5 s and supernatant was discarded. 12 ml of KRB was 
added and mixed. The tube was centrifuged at 825 x g for 5 s and supernatant was discarded. 
After addition of 12 ml of KRB, the tube was centrifuged at 465 x g for 5 s. After the 
supernatant being discarded, 7 ml KRB was added and mixed. The mixture was then 
transferred by pipette to a 30-mm Petri dish that contained 1 ml of KRB solution. The 
pancreatic islets were collected under a dissecting microscope in the laminar flow hood. The 
pancreatic islets were cultured in RPMI 1640, supplemented with 10 % FBS, penicillin (100 
U/ml), and streptomycin (100 µ,g/ml), for 3 days. 
Experimental design 
Pancreatic islets were randomly placed into 1.5-ml microcentrifuge tubes to yield 3 
islets per tube in 0.5 ml KRB for staic incubation. The tubes were centrifuged for 5 min at 
180 x g. The supernatant was discarded and 0.5 ml KRB was again added to each tube. Islets 
were preincubated for 60 min at 37 ° C. Subsequently, the tubes were centrifuged for 5 ·min 
at 180 x g and the supernatant was collected. Treatments in 0.5 ml KRB were added and the 
tubes were incubated for 40 min at 3 7 ° C. The tubes were centrifuged for 5 min at 180 x g. 
The supernatant samples were collected and kept at 4 ° C and subsequently assayed for 
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insulin using radioimmunoassay (RIA) [ 15]. Porcine insulin donated by Eli Lilly & company 
(Indianapolis, In, USA) was used as standards for the RIA. 
Data expression and analysis 
Data of supernatant concentrations of insulin were expressed as a percentage of the 
basal control (5.5 mM glucose) in mean± SE. Data was analyzed by one-way analysis of 
variance (ANOVA). Tukey's Honestly Significant Difference test was used to determine 
differences between treatments for which the ANOV A indicated a significant (P<0.05) F 
ratio. 
Results 
Somatostatin-induced inhibition of insulin release 
In a preliminary experiment, 1 µM SST only inhibited the basal control insulin 
release by 18 % ( data not shown). Therefore we decided to study the inhibitory effect of SST 
on glucose-induced insulin release. In this experiment, 20 mM glucose evoked 5.5 fold 
insulin release over the basal control (Figure 1 ). In the presence of 20 rnM glucose, SST (1 -
100 nM) inhibited insulin release in a dose-dependent manner (Figure 1 ). The EC50 of SST 
was 0.38 ± 0.10 nM. SST failed to inhibit glucose induced-insulin release at 0.01 and 0.1 nM. 
SST abolished glucose induced-insulin release at 100 nM. 
Effect of SSTR agonists on insulin release 
A number of SSTR agonists at 1 µM each were tested to determine which would 
inhibit glucose-induced insulin release. In this experiment, 20 mM glucose evoked a 6 fold 
insulin release over the basal control (Figure 2). SSTRl agonist L-797,591, SSTR3 agonist 
L-796,778, SSTR4 agonist L-803,087, and SSTR5 agonist L-817,818 failed to inhibit 20 mM 
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glucose-induced insulin release (Figure 2). In contrast, 1 µ,M SSTR2 agonist L-779,976 and 
100 nM SST abolished glucose-induced insulin release (Figure 2). The results suggested that 
SSTR2 mediates SST-induced inhibition of insulin release . 
Dose-dependency of SSTR2 agonist L-779,976 in inhibiting insulin release 
L-779,976 (0.1 - 100 nM) inhibited glucose-induced insulin release in a dose-
dependent manner (Figure 3). The EC50 ofL-779,976 was 0.57 ± 0.14 nM. L-779,976 failed 
to inhibit glucose-induced insulin release at 0.01 nM. L-779,976 caused the maximal 
inhibition on glucose-induced insulin release at 100 nM. 
Effect of SSTR2 antagonist PRL-2903 011 SST-induced inhibition of insulin release 
Pretreatment with PRL-2903 (300 nM, and 1 µ,M) antagonized SST (100 nM)-induced 
inhibition of glucose-induced insulin release in a dose-dependent manner (Figure 4). The 
EC50 of PRL-2903 was 315.50 ± 30.56 nM. Pretreatment with 30 nM and 100 nM PRL-2903 
for 10 min failed to antagonize SST (100 nM)-induced inhibition of insulin release. 
Pretreatment with 1 µ,M PRL-2903 for 10 min abolished the SST (100 nM)-induced 
inhibition of insulin release. Treatment with 1 µ,M PRL-2903 alone did not change insulin 
release ( data not shown). 
Discussion 
In humans, rats and mice, SST inhibits insulin release via SSTR5 [9, 10, 11]. In the 
present study, we used nonpeptide SSTR agonists, which are highly specific to individual 
SSTR subtypes [2, 13], to functionally characterize the SSTR in hamster islets that mediates 
SST-induced inhibition of insulin release. L-779,976, a SSTR2 agonist, inhibited insulin 
release in a dose-dependent manner, whereas agonists for SSTRl, 3, 4, and 5 failed to inhibit 
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insulin release. In addition, PRL-2903 , a SSTR2 antagonist, antagonized the effect of SST in 
a dose-dependent manner as well. Our findings suggest that in hamster ~-cells, SST inhibits 
insulin release via SSTR2. This is the first study that clearly indicates the involvement of 
SSTR2, but not SSTR5, in the inhibition of insulin release. 
The specific SSTR that mediates the inhibition of insulin release in humans is 
controversial. Zambre et al. suggested that SSTR5 mediate the inhibition of insulin release 
[11], whereas Brunicardi et al. suggested that SSTR2 mediate this effect [16, 17]. In the 
study by Zambre et al., human islets were freshly isolated from heart-beating cadaveric organ 
donors. The SSTR5 peptide agonists BIM 23268 and BIM 23313 (1 - 100 nM) inhibited 
glucose (20 mM)-induced insulin release in a dose-dependent manner. In contrast, a group of 
SSTR2 peptide agonists failed to inhibit insulin release [ 11]. Brunicardi et al. utilized 
perfused cadaveric human pancreas model to determine the effect of SSTR agonists. They 
found that DC 32-87 (or NC8-12), a SSTR2 agonist, inhibited the basal insulin release at :2'.5 
ng/ml ( or 4.4 nM), whereas DC 32-92, a SSTR 5 agonist (25 ng/ml or 22 nM), failed to do 
so. However, the responsiveness of the pancreata in these experiments is a serious concern 
because the perfusion experiments using cadaveric pancreata lasted 3-6 hours [16, 17]. As a 
result, the pancreata failed to respond to 16. 7 mM glucose as a secretagogue at the end of 
each experiment [16]. It appears that the human islet study by Zambre et al [11] . yielded 
more credible results than the human perfused pancreas study by Brunicardi et al [16, 17], 
and suggested that SST inhibits insulin release in human ~-cells via SSTR5. 
In conclusion, although it is generally accepted that SSTR5 mediates SST-induced 
inhibition of insulin release in other species, our present findings suggest that in hamsters, 
SSTR2, but not SSTR5, mediates SST-induced inhibition of insulin release. This is the first 
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time that SSTR2 has been clearly indicated to mediate the inhibitory effect of SST on insulin 
release. Our findings further suggest SSTR2 fulfills an important physiological function in 
the hamster endocrine pancreas. 
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FIGURE LEGENDS 
Fig. 1. Inhibitory effect of SSTon glucose-induced insulin release. All data are expressed as 
percent of the basal control group. Val us are mean± SEM (n = 3 independent experiments 
with duplicates in each experiment). *, P<0.05 vs. the glucose alone group. Insulin 
concentration in the basal control group was 250 ± 50 pg / islet / 40 min. 
Fig. 2. Effect of SSTR agonists on glucose-induced insulin release. All data are expressed as 
percent of the basal control group. Valus are mean± SEM (n = 3 independent experiments 
with duplicates). Glu, glucose; *, P<0.05 vs. the glucose alone group. Insulin concentration 
in the basal control group was 150 ± 30 pg / islet / 40 min. 
Fig. 3. Inhibiton by SSTR2 agonist L-779,976 of glucose-induced insulin release. All data 
are expressed as percent of the basal control group. Valus are mean± SEM (n = 4 
independent experiments with duplicates). *, P<0.05 vs. the glucose alone group. Insulin 
concentration in the basal control group was 125 ± 38 pg / islet / 40 min. 
Fig 4. Effect of SSTR2 antagonist PRL-2903 on SST-induced inhibition of insulin release. 
All data are expressed as percent of the basal control group. Valus are mean± SEM (n = 5 
independent experiments with duplicates) . Glu, glucose;*, P<0.05 vs. the SST+ glucose 
group. Insulin concentration in the basal control group was 130 ± 30 pg / islet / 40 min. 
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Table 1. Binding affinities of SSTR peptide agonists and non peptide agonists for the 
clonal human SSTRs (modified from Hocart et al., 1999 and Patel 1999). 
Compound hSSTRl hSSTR2 
Peptide agonists 
DC32-87 7820 0.65 
Nonpeptide agonists 
L-797,591 1.4 1875 
L-779,976 2760 0.05 
L-796,778 1255 >10,000 
L-803,087 199 4720 
L-817,818 3.3 52 
ICso (nM) 
hSSTR3 
244 
2240 
729 
24 
1280 
64 
hSSTR4 
970 
170 
310 
8650 
0.7 
82 
hSSTR5 
6.8 
3600 
4260 
1200 
3880 
0.4 
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